Status:
COMPLETED
Corticosteroid Therapy of Septic Shock - Corticus
Lead Sponsor:
Hadassah Medical Organization
Collaborating Sponsors:
European Society of Intensive Care Medicine
International Sepsis Forum
Conditions:
Shock, Septic
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of the study is to determine whether steroids decrease 28-day mortality in patients with septic shock.
Detailed Description
The use of steroids in septic shock remains controversial. The purpose of this study is to determine whether hydrocortisone decreases 28-day mortality in patients with septic shock. The primary end po...
Eligibility Criteria
Inclusion
- Clinical evidence of infection within the previous 72 hours (may be present longer than 72 hours) (a, b, c, or d - only 1 required)
- Presence of polymorphonuclear cells in a normally sterile body fluid (excluding blood);
- Culture or Gram stain of blood, sputum, urine or normally sterile body fluid positive for a pathogenic micro-organism;
- Focus of infection identified by visual inspection (e.g. ruptured bowel with the presence of free air or bowel contents in the abdomen found at the time of surgery, wound with purulent drainage);
- Other clinical evidence of infection - treated community acquired pneumonia, purpura fulminans, necrotising fascitis, etc.
- Evidence of a systemic response to infection as defined by the presence of two or more of the following signs within the previous 24 hours. These signs may be present longer than 72 hours.
- Fever (temperature \>38.3°C) or hypothermia (rectal temperature \< 35.6°C);
- Tachycardia (heart rate of \>90 beat/min);
- Tachypnea (respiratory rate \> 20 breaths/min, PaC02\<32 mmHg) or patient requires invasive mechanical ventilation;
- Alteration of the WBC count \>12,000 cells/mm3, \<4,000 cells/mm3 or \>10% immature neutrophils (bands).
- Evidence of shock defined by (A + B- both required within the previous 72 hours (may NOT be present longer than 72 hours).
- A. A systolic blood pressure \< 90 mmHg or a decrease in SBP of more than 50 mmHg from baseline in previous hypertensive patients (for at least one hour) despite adequate fluid replacement OR need for vasopressors for at least one hour (infusion of dopamine ≥ 5 mcg/kg/min or any dose of adrenaline, noradrenaline, phenylephrine or vasopressin) to maintain a SBP ≥ 90 mmHg;
- B. Hypoperfusion or organ dysfunction which is not the result of underlying diseases or drugs, but is attributable to sepsis, including one of the following:
- Sustained oliguria (urine output \< 0.5 ml/kg/hr for a minimum of 1 hour)
- Metabolic acidosis \[pH of \< 7.3, or a base deficit of \> or = 5.0 mmol/L, or an increased lactic acid concentration (\> 2 mmol/L)\].
- Arterial hypoxemia (Pa02/FI02\<280 in the absence of pneumonia)(Pa02/FI02\<200 in the presence of pneumonia).
- Thrombocytopenia - platelet count ≤ 100,000 cells/mm3.
- Acute altered mental status (Glasgow Coma Scale \< 14 or acute change from baseline).
- 4\. Informed Consent
- 5\. Cortisol level at baseline and 60 minutes after 0.25 mg cosyntropin
Exclusion
- Pregnancy
- Age less than 18.
- Underlying disease with a prognosis for survival of less than 3 months.
- Cardiopulmonary resuscitation within 72 hours before study.
- Drug-induced immunosuppression, including chemotherapy or radiation therapy within 4 weeks before the study.
- Administration of chronic corticosteroids in the last 6 months or acute steroid therapy (any dose) within 4 weeks (including inhaled steroids). Topical steroids are not exclusions.
- HIV positivity.
- Presence of an advanced directive to withhold or withdraw life sustaining treatment (i.e. DNR).
- Advanced cancer with a life expectancy less than 3 months.
- Acute myocardial infarction or pulmonary embolus.
- Another experimental drug study within the last 30 days.
- Moribund patients likely to die within 24 hours.
- Patients in the ICU for more than 2 months at the time of the start of septic shock.
Key Trial Info
Start Date :
March 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2005
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT00147004
Start Date
March 1 2002
End Date
November 1 2005
Last Update
April 24 2008
Active Locations (57)
Enter a location and click search to find clinical trials sorted by distance.
1
LKH Feldkirch
Feldkirch, Austria, A-6800
2
KH-BHS Linz
Linz, Austria, A-4010
3
Krankenhaus der Barmherzigen Schwestern Ges. mbH
Linz, Austria, A-4010
4
Universitaetsklinik fuer Innere Medizin II
Vienna, Austria, A 1090